Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Quetiapine

Plain-language summaryIntrigue 65 / 100

Quetiapine (Seroquel) is a workhorse atypical antipsychotic from AstraZeneca, approved in 1997, that has become equally famous as an off-label sleep aid because its potent histamine-receptor blockade makes the low-dose form (25 to 100 mg) profoundly sedating. At full antipsychotic doses (300 to 800 mg) it is used for schizophrenia and acute mania. At intermediate doses (150 to 300 mg) it is FDA-approved for bipolar depression and as add-on for major depression. The active leftover after liver metabolism, norquetiapine, blocks the norepinephrine pump and contributes to the antidepressant effect. Metabolic side effects (weight gain, lipid and glucose disturbance) are real and dose-related, which has prompted concern about its widespread use as a sleep drug. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Well-evidenced atypical antipsychotic; low novelty, the norquetiapine metabolite angle is its only remaining research hook

Look, quetiapine is about as far from a frontier compound as you can get. Approved by the FDA in 1997, it’s had nearly three decades of clinical scrutiny across schizophrenia, bipolar disorder, and adjunctive MDD, and the literature is enormous. That massive evidence base is real and we’d never dispute the clinical utility. But clinical utility isn’t what this library is scoring, and on novelty and differentiation, quetiapine earns almost nothing.

The receptor profile is famously broad: 5-HT2A, H1, alpha-1, 5-HT1A partial agonism, and a D2 Ki of roughly 770 nM that makes it the weakest D2 binder in the class. That weak D2 story was actually interesting at one point, back when investigators were trying to understand why some atypicals showed fewer extrapyramidal effects. But that conversation is decades old and well-resolved. The mechanism that still earns quetiapine some research attention is the norquetiapine metabolite angle: norquetiapine is a potent NET inhibitor (Ki around 35 nM) and a 5-HT2C antagonist, which explains the compound’s antidepressant signal and its FDA approval as an MDD adjunct. Thats genuinely interesting pharmacology; a real example of a case where the metabolite carries a mechanistically distinct payload from the parent. We like that story. What we don’t like is that the story is also well-characterized at this point, with the norquetiapine mechanism essentially textbook since the early 2010s.

The translational and evidence scores are high because quetiapine simply has an exceptional clinical database. Multiple phase 3 trials across multiple indications, replicated over years, with regulatory consensus in several jurisdictions. If you want a reference atypical antipsychotic for mechanism work or as a comparison arm in a preclinical model, quetiapine is a reasonable choice. That’s real bench value and we’re crediting it. But a reference compound isn’t the same as an indispensable probe, and nothing about quetiapine’s mechanism lets you answer a question you genuinely couldn’t answer with a contemporary or successor compound.

The off-label hypnotic use, which is where most investigators encounter it outside psychiatry, is an honest embarrassment. Using a broad-spectrum atypical at 25 to 100 mg for sleep is largely an H1-mediated antihistamine effect, and the side-effect burden relative to that marginal signal is hard to defend. No serious investigator is building a sleep research program around this compound right now.

What quetiapine is, in the end, is a well-understood and clinically important drug that happens to have a metabolite worth knowing about. The norquetiapine/NET angle is genuinely interesting as a case study in active metabolite pharmacology. The compound itself as a research target scores where it scores: high on evidence, low on novelty, and not particularly differentiated in a very crowded class.

Novelty

18

Mechanism promise

38

In-category differentiation

28

Evidence quality

82

Translational signal

75

Research bench value

45

Rationale Quetiapine’s near-three-decade clinical history yields high evidence and translational scores, but novelty and differentiation are floor-level for an approved drug in a crowded antipsychotic class; the norquetiapine NET inhibitor story keeps mechanism and bench value from bottoming out but doesn’t rescue the overall.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic

A dibenzothiazepine atypical antipsychotic with broad receptor binding; the active metabolite norquetiapine is a NET inhibitor contributing to antidepressant efficacy.

Abstract

Quetiapine (2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)ethoxy]ethanol; CAS 111974-69-7; molecular formula C21H25N3O2S; molecular weight 383.51) is a dibenzothiazepine atypical antipsychotic developed at AstraZeneca and approved by the FDA in 1997 under the trade name Seroquel. The receptor profile is broad: D2 (Ki approximately 770 nM, the weakest of the antipsychotic class), 5-HT2A (Ki approximately 295 nM), H1 (Ki approximately 11 nM), alpha-1 (Ki approximately 22 nM), 5-HT1A partial agonism. The active metabolite norquetiapine (formed via CYP3A4) is a potent NET inhibitor (Ki approximately 35 nM) and a 5-HT2C antagonist, contributing to antidepressant efficacy and supporting the FDA-approved adjunctive use in major depressive disorder. Plasma half-life is 6 to 7 hours; metabolism is via CYP3A4. Approved for schizophrenia, bipolar I disorder (mania, depression, maintenance), and adjunctive in MDD. Off-label use as a hypnotic at 25 to 100 mg is widespread despite a poor efficacy-to-side-effect ratio for that indication. Used as a reference broad-spectrum atypical antipsychotic in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-233Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Clozapine

Plain-language summaryIntrigue 78 / 100

Clozapine (Clozaril) is the most effective antipsychotic ever developed, and it has held that title since the 1980s without serious challenger. It was approved by the FDA in 1989 specifically for treatment-resistant schizophrenia and remains the only drug demonstrated to reduce suicidality in schizophrenia. The catch is severe: roughly one in 100 patients develops agranulocytosis, a potentially fatal collapse of white blood cell production, which is why every patient on clozapine in the United States must submit to weekly, then biweekly, then monthly blood draws indefinitely. Mechanistically it is the prototype atypical antipsychotic, with weak D2 blockade compensated by potent 5-HT2A blockade and a wide net of effects on histamine, muscarinic, and adrenergic receptors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

57/100

Gold standard for treatment-resistant schizophrenia but low novelty and exhausted mechanism space limit research appeal

Look, clozapine is one of the most clinically important psychiatric compounds in modern medicine. The gold standard for treatment-resistant schizophrenia since the early 1990s, it consistently outperforms every other antipsychotic in TRS populations across decades of multi-center trials. That 1% agranulocytosis incidence is genuinely dangerous and the weekly CBC monitoring requirement through the first six months is a real burden on both patient and system, and still no other drug in the class has managed to displace it for TRS. That clinical track record is not marketing. Its real, its replicated, and its durable.

The receptor pharmacology is what put clozapine on the map as a research object. The weak D2 antagonism (Ki ~130 nM) paired with potent 5-HT2A antagonism (Ki ~16 nM), plus a broad off-target profile spanning D4, muscarinic M1-M5, H1, alpha-1, and multiple 5-HT subtypes, gave investigators the receptor-binding template that defined the entire atypical antipsychotic class. The M1 affinity (Ki ~7 nM) is particularly interesting for anyone studying muscarinic contributions to cognition or psychosis. The M4 partial agonism that produces paradoxical hypersalivation in an otherwise anticholinergic compound is one of the genuinely under-worked threads still worth pursuing.

Here’s the thing though: as a forward-looking research target, novelty is a real problem. This is a 1989 approved drug whose core mechanism has been studied exhaustively for 35 years. The atypical class it spawned has been dissected from every angle conceivable. The literature isnt sparse, its saturated. You can open any receptor pharmacology textbook and find clozapine used as the canonical example. Investigators reach for it precisely because the answers are known, not because theres something new to find. Thats the opposite of an underexplored compound.

What keeps clozapine relevant in a research library is its probe and comparator value. For anyone working on antipsychotic mechanism studies, its the reference everyone is implicitly measuring against. For investigators studying TRS biology, its essentially the only validated positive control. For labs interrogating D4 receptor function specifically, clozapines selectivity profile is still a useful tool despite the years. We think the M4 partial agonism angle and the CYP1A2 metabolism interactions (particularly in smokers, who dramatically accelerate clearance) remain underexplored relative to the compounds clinical importance.

Honestly, the positioning is this: outstanding evidence quality, strong translational signal, real bench probe value in the right context, but genuinely low novelty and a mechanism space that most investigators have already mapped thoroughly. For a lab focused on whats next in CNS pharmacology, clozapine is background knowledge. For a lab working specifically on treatment resistance mechanisms, comparative antipsychotic pharmacology, or muscarinic-dopamine crosstalk, it earns its place on the bench.

Novelty

20

Mechanism promise

40

In-category differentiation

65

Evidence quality

82

Translational signal

78

Research bench value

75

Rationale Clozapine earns strong marks on evidence quality, translational signal, and bench probe value given its canonical reference-compound role and unmatched TRS clinical record, but 1989 FDA approval, fully characterized multireceptor pharmacology, and a thoroughly saturated literature drag novelty and mechanism scores down sharply. No scheduling cap or structural category cap applies; the score reflects a genuinely important but mature compound with limited frontier value for forward-looking research programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic / D4-D2 multireceptor antagonist

The prototype atypical antipsychotic; the gold standard for treatment-resistant schizophrenia, limited by agranulocytosis risk requiring weekly blood monitoring.

Abstract

Clozapine (8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; CAS 5786-21-0; molecular formula C18H19ClN4; molecular weight 326.82) is a dibenzodiazepine atypical antipsychotic developed at Wander/Sandoz and approved by the FDA in 1989 under the trade name Clozaril. The compound is the prototype atypical antipsychotic, introducing the receptor profile that defines the class: weak D2 antagonism (Ki approximately 130 nM) combined with potent 5-HT2A antagonism (Ki approximately 16 nM), producing antipsychotic efficacy without the extrapyramidal symptoms typical of high-affinity D2 antagonists. Off-target activity is broad: H1, alpha-1, muscarinic M1-M5 (Ki approximately 7 nM at M1), 5-HT2C, 5-HT3, 5-HT6, 5-HT7 antagonism, contributing to sedation, weight gain, sialorrhea (paradoxical from M4 partial agonism), and orthostatic hypotension. The defining clinical feature is efficacy in treatment-resistant schizophrenia, where clozapine consistently outperforms other antipsychotics; the limitation is approximately 1 percent agranulocytosis incidence, requiring weekly CBC monitoring through the first 6 months and biweekly thereafter. Plasma half-life is 12 hours; metabolism is via CYP1A2 (primary), CYP3A4, CYP2D6. Used as the canonical atypical antipsychotic in mechanism studies and as the gold standard for treatment-resistant schizophrenia.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-232Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sembragiline

Plain-language summaryIntrigue 40 / 100

Sembragiline is an investigational selective reversible MAO-B inhibitor from Roche and EVOTEC, originally developed as a possible Alzheimer disease treatment. The rationale was elegant: MAO-B is upregulated in the reactive astrocytes that surround amyloid plaques in Alzheimer brain tissue, and that upregulation contributes to oxidative damage. Selectively shutting it down with a reversible blocker should, in theory, reduce that damage without interfering with normal brain function. The Phase 2 MAyflOwer RoAD trial in mild-to-moderate Alzheimer disease failed to show clinical benefit, however, and development was halted. The compound retains research value as a mechanistic probe but has no clinical future. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

38/100

Failed Alzheimer phase 2 candidate with residual tool value as a clean reversible selective MAO-B probe

Look, sembragiline is a clean story about a drug that asked the right question and got the wrong answer. The mechanistic rationale was genuinely reasonable: MAO-B is upregulated in reactive astrocytes in Alzheimer brain tissue, it contributes to oxidative stress, and there’s a plausible chain from that to amyloid pathology. Roche and Evotec built a highly selective reversible inhibitor to probe this, with a selectivity ratio above 1000:1 over MAO-A. Thats pharmacologically elegant. The reversibility angle was the key idea: unlike selegiline or rasagiline, which ablate MAO-B activity for the life of the enzyme, sembragiline gives you tunable, titratable inhibition without committing to an irreversible mechanism.

Then the MAyflOwer RoAD trial happened. Phase 2, n=542, mild-to-moderate Alzheimer disease, 52 weeks. No significant slowing of cognitive decline. Development halted. The compound didn’t fail because of bad pharmacology; it failed because the hypothesis didn’t translate. MAO-B inhibition in Alzheimer’s turned out not to be a sufficient lever on disease progression, at least not at the population level or the dose ranges tested.

What’s left is a genuinely useful but narrow tool compound. Academic neuroscience groups use sembragiline specifically because of what it is: the reference reversible selective MAO-B inhibitor with the cleanest selectivity profile available. If you’re studying MAO-B’s contribution to neuroinflammatory signaling, dopamine metabolism in Parkinson’s-adjacent biology, or oxidative stress dynamics in reactive astrocytes, you need something that lets you toggle the enzyme without the complication of irreversibility. Safinamide is also reversible and approved, but it carries a sodium channel component that complicates clean mechanistic attribution. Sembragiline is cleaner for this purpose.

We think the bench value is real but specific. If your research program touches MAO-B biology directly, this is worth having and using. If it doesn’t, theres not much here. The failed phase 2 is decisive for the Alzheimer’s indication, and the compound has no obvious pivot to another indication with real human signal. Novelty is modest: MAO-B inhibition is a mature mechanistic class, and reversible selectivity within it is a refinement, not a new direction.

Honestly, what keeps this at 38 is arithmetic. The mechanism class is established, the clinical hypothesis was falsified, and the tool value is specific enough to matter only to a subset of neuroscience programs. Sembragiline ran a clean trial and learned something real. That’s exactly what research should do. It just doesn’t make the compound a priority target for most investigators, and the score should say so plainly.

Novelty

32

Mechanism promise

35

In-category differentiation

48

Evidence quality

44

Translational signal

22

Research bench value

55

Rationale Sembragiline’s mechanistic rationale was scientifically sound but the MAyflOwer RoAD trial (n=542, 52 weeks) produced a clear null result, decisively closing the AD indication. Its remaining value is as the reference reversible, highly selective MAO-B inhibitor (greater than 1000:1 over MAO-A) for academic studies of MAO-B’s contribution to neurodegeneration, but that utility is narrow enough that bench_value can’t rescue the overall from niche-probe territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective reversible MAO-B inhibitor (investigational)

A selective reversible MAO-B inhibitor investigated for Alzheimer disease; failed phase 2 efficacy.

Abstract

Sembragiline (EVT-302, RG1577; molecular formula C19H22FN3O; molecular weight 327.40) is a selective reversible MAO-B inhibitor developed at Roche and EVOTEC as a candidate for Alzheimer disease. The mechanistic rationale: MAO-B is upregulated in reactive astrocytes in Alzheimer brain tissue, contributing to oxidative stress and amyloid pathology; selective reversible inhibition might reduce this contribution without the irreversible enzyme abolition of selegiline or rasagiline. Phase 2 MAyflOwer RoAD trial in mild-to-moderate Alzheimer disease (n=542) failed to show significant slowing of cognitive decline at 52 weeks; development was halted. The compound retains research utility as a clean tool for selective reversible MAO-B inhibition (selectivity ratio greater than 1000:1 over MAO-A) and is used in academic studies of MAO-B’s role in neurodegeneration. Used as the reference reversible selective MAO-B inhibitor in academic neuroscience.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-231Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Toloxatone

Plain-language summaryIntrigue 38 / 100

Toloxatone (Humoryl) is a French reversible MAO-A inhibitor from Delalande, approved in France in 1984. Like moclobemide and pirlindole it can be displaced from the enzyme by dietary tyramine, which means patients can eat aged cheese without triggering a hypertensive crisis. The drug had a brief moment of relevance in French psychiatry but never spread to other markets, was not pursued for FDA approval, and was eventually discontinued in France in the 2000s as newer antidepressants displaced it. It is mostly of historical interest now, although it remains a useful research probe for MAO-A pharmacology because of its clean mechanism. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

25/100

A 1984 French RIMA overtaken by moclobemide; minimal novelty, thin evidence base, shrinking research relevance

Look, toloxatone is a compound that made sense in 1984. Delalande was doing real chemistry, the RIMA concept was genuinely interesting at the time, and getting a reversible MAO-A inhibitor that didn’t require tyramine restriction was a meaningful step away from the irreversible MAOI era. We get that. But we’re not rating it for 1984.

The mechanism is single-enzyme competitive inhibition of MAO-A. That’s it. There’s no dual target story, no allosteric angle, no novel downstream pathway. MAO-A biology is about as well-mapped as neurochemistry gets at this point, and the RIMA concept was fully articulated and validated long before this compound hit its peak. Moclobemide became the reference RIMA because it has broader international approval, more trial data, and a cleaner pharmacological record. Toloxatone sits behind it on every dimension that matters to a working investigator.

The evidence situation is genuinely thin by current standards. French MDD trials from the 1980s were sufficient for a French approval in a different regulatory climate, but that literature hasn’t grown in any meaningful way. The compound never cleared regulatory review outside France. Clinical use has substantially declined, which is the field voting with its feet. There’s no live clinical program, no recent phase 2 data, nothing in ClinicalTrials.gov worth flagging. What you have is historical evidence that it works roughly as expected for a RIMA, which isn’t the same as having evidence that it does anything moclobemide doesn’t.

The only honest positive we can offer is the bench probe angle. The abstract notes it’s used as a reference oxazolidinone RIMA in mechanism studies, and thats real, if narrow. If you’re specifically studying the oxazolidinone scaffold or doing comparative binding work across RIMA chemotypes, toloxatone gives you a specific structural reference that moclobemide doesn’t. That’s a genuine, if limited, use case. But it doesn’t move the needle much for most programs.

Honestly, the compound reads like a chapter in the history of antidepressant pharmacology rather than an active research target. Investigators working on MAO biology will reach for moclobemide, harmaline derivatives, or clorgyline depending on selectivity needs. There’s no scenario where toloxatone is the first or second choice. The score reflects a real compound with real historical evidence that has been quietly made irrelevant by better alternatives and a mechanism that no longer surprises anyone.

Novelty

18

Mechanism promise

22

In-category differentiation

18

Evidence quality

32

Translational signal

38

Research bench value

28

Rationale Toloxatone scores low across the board because it’s a four-decade-old regional approval with no international uptake, a well-understood single-enzyme mechanism that moclobemide executes better, and an evidence base that never cleared the bar for approval outside France. The oxazolidinone scaffold gives it marginal probe identity but not enough to rescue the score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Reversible MAO-A inhibitor

A 5-(hydroxymethyl)oxazolidinone RIMA approved in France in 1984; an early-generation reversible inhibitor of MAO-A.

Abstract

Toloxatone (5-(hydroxymethyl)-3-(3-methylphenyl)oxazolidin-2-one; CAS 29218-27-7; molecular formula C11H13NO3; molecular weight 207.23) is an oxazolidinone RIMA developed at Delalande in France and approved there in 1984 under the trade name Humoryl. The compound is a reversible competitive MAO-A inhibitor with a clinical profile broadly comparable to moclobemide; selectivity for MAO-A over MAO-B is approximately 50-fold at therapeutic concentrations. Plasma half-life is approximately 2 hours; hepatic metabolism is the primary clearance pathway. Tyramine restriction is not required at clinical doses. Clinical efficacy in major depressive disorder was demonstrated in French trials but the drug never received approval outside France and clinical use has substantially declined. Used historically and as a reference oxazolidinone RIMA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-230Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pirlindole

Plain-language summaryIntrigue 51 / 100

Pirlindole (Pyrazidol) is the Soviet-era reversible MAO-A inhibitor, developed at the Soviet Academy of Sciences in the 1970s and registered in the USSR in 1975, several years before Roche’s moclobemide reached European markets. Mechanistically it does the same job as moclobemide (reversible MAO-A blockade) but with a chemical scaffold completely unlike its Western counterpart, plus a side-activity blocking 5-HT2 serotonin receptors that may contribute to its mood effects. Russian and Eastern European clinicians have been using it for nearly fifty years for depression. The Western literature on it is thin, partly because it never went through Western regulatory review and partly because most of its trials were published in Russian-language journals. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

25/100

Soviet RIMA with dual mechanism but murky evidence base and minimal Western research utility

Look, pirlindole has a genuine footnote in psychopharmacology history. Developed at the Soviet Academy of Sciences and registered as Pyrazidol in 1975, it predates moclobemide’s Western arrival by over a decade and makes a credible claim to being the first reversible MAO-A inhibitor in actual clinical use. The pyrazinocarbazole scaffold is structurally distinct from the benzamide class moclobemide belongs to, and the secondary 5-HT2 antagonism gives it a combined pharmacological profile that, on paper, looks more interesting than a pure RIMA story. That combination, RIMA plus 5-HT2 blockade, resembles the rough logic of compounds like mirtazapine, which has real antidepressant signal with a different side-effect signature. So the mechanism isnt boring. It’s just not novel in 2026.

The real problem is the evidence base. Pirlindole’s clinical literature is almost entirely Soviet and post-Soviet, which creates a verification problem that’s hard to overstate. The trials exist, the approvals are real, and the compound has been prescribed in Russia for five decades. But the trial methodology, data accessibility, and replication status don’t map cleanly onto what a Western systematic reviewer or meta-analyst would accept. We’re not saying the compound doesnt work. We’re saying that in 2026, a bench scientist building a research program on MAO-A inhibition would default to moclobemide as the reference RIMA because the supporting literature is accessible, replicated, and methodologically characterizable.

What we’d want someone to understand is the sourcing reality. Outside Russia and a handful of former Soviet states, pirlindole is not registered and is genuinely difficult to source at research quality. That practical constraint compounds the evidence problem. If you want to study the RIMA component in isolation, moclobemide. If you want 5-HT2 pharmacology in isolation, ketanserin or pimavanserin. Pirlindole as a combined probe is conceptually interesting but lacks the accessibility and documentation to function well as a tool.

The RIMA class itself is in an awkward spot. Contemporary monoamine pharmacology interest has shifted toward MAO-B inhibition in neurodegeneration, or toward multimodal combinations pairing serotonin transporter work with specific receptor subtype targeting. Pirlindole doesnt slot cleanly into either conversation. For a narrow comparative pharmacology program studying the Soviet drug development tradition or specifically probing the RIMA/5-HT2 combination in animal models where sourcing is feasible, theres a case. Outside that framing, the research opportunity cost is high and the available alternatives are clearly better documented.

Novelty

18

Mechanism promise

30

In-category differentiation

22

Evidence quality

22

Translational signal

35

Research bench value

22

Rationale Pirlindole is a 50-year-old reversible MAO-A inhibitor whose entire clinical history lives in Soviet and post-Soviet literature, making evidence quality epistemically difficult to evaluate by modern standards. The secondary 5-HT2 antagonism is a mildly interesting differentiator but not sufficient to lift a compound that more selective and better-documented tools can surpass on every axis.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical reversible MAO-A inhibitor

A pyrazinocarbazole RIMA developed in the USSR in the 1970s; the historical Soviet RIMA equivalent.

Abstract

Pirlindole (2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-jk]carbazole; CAS 60762-57-4; molecular formula C15H18N2; molecular weight 226.32) is a pyrazinocarbazole RIMA developed at the Soviet Academy of Sciences in the 1970s and registered in the USSR in 1975 under the trade name Pyrazidol. The compound is a reversible competitive MAO-A inhibitor with secondary 5-HT2 antagonism contributing to its antidepressant profile. Clinical efficacy has been documented in Soviet and post-Soviet trials in major depressive disorder, dysthymia, and reactive depression; head-to-head data versus moclobemide are sparse. Plasma half-life is approximately 2 to 4 hours; metabolism is hepatic. The compound is well tolerated relative to hydrazine MAOIs and does not require tyramine restriction at clinical doses. Approval is restricted to Russia and former Soviet states; not registered in the US, EU, or other Western markets. Used as the historical reference RIMA from the Soviet pharmacological tradition.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-229Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Moclobemide

Plain-language summaryIntrigue 62 / 100

Moclobemide (Aurorix) was a major step forward in MAOI design: it blocks MAO-A reversibly rather than permanently, which means dietary tyramine can simply outcompete the drug at the enzyme rather than triggering a crisis. That eliminates the dreaded cheese-effect that has held the older MAOIs back for sixty years. Roche brought it to market in Europe in 1989 and in Canada in 1992, but it never received FDA approval in the US, partly because the company’s Phase 3 trials were not designed to American regulatory standards. Efficacy in depression and social anxiety is solid in European data, comparable to SSRIs. Without the FDA stamp it remains underused in North American practice, which is unfortunate because it is genuinely a more elegant drug than its first-generation predecessors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

42/100

Canonical RIMA reference probe with real MAO-A selectivity utility; clinical edge never materialized

Look, moclobemide had a real idea. Irreversible MAOIs work, but the tyramine interaction is a legitimate safety ceiling that limits who you can put on them. Roche’s morpholine benzamide solved that by binding MAO-A reversibly — tyramine from a meal can simply outcompete it, so the cheese reaction risk collapses. That was a clean piece of pharmacology, and it earned the drug approvals across Europe and Canada through the early nineties. Here’s the thing though: the tyramine story was supposed to be the commercial unlock and it wasnt. Head-to-head against TCAs, moclobemide comes out modestly inferior on efficacy endpoints in most published comparisons. It never crossed the FDA finish line. The class it defines — RIMAs — has stayed small and the compound itself has stayed niche.

The mechanism is single-enzyme inhibition. MAO-A selectivity is roughly 100:1 over MAO-B at low doses, which is clean but not exciting by 2026 standards. We’re scoring mechanism against a landscape that includes dual incretins, mitochondrial peptides, and NMDA channel allosteric modulators. Selective reversible inhibition of one well-mapped enzyme in a saturated antidepressant class just doesn’t move the needle. What you get is predictable: serotonin and norepinephrine accumulation through reduced oxidative deamination, half-life of one to four hours, CYP2C19 clearance, twice-daily dosing. Nothing here is opaque.

Where moclobemide earns its score is bench utility. If your research question involves parsing MAO-A vs MAO-B contributions to a phenotype, moclobemide is the tool. It lets you probe MAO-A selectively and reversibly in a way that neither the irreversible drugs nor the less selective agents allow. Wash-out is fast given the short half-life, which matters for crossover designs. We’d describe it as the selegiline counterpart for MAO-A work — not exciting in isolation, but the right instrument when the question specifically calls for it. The social anxiety disorder literature also gives it a respectable translational footprint; the human signal is genuine even if effect sizes are modest.

The differentiation score reflects its position as the canonical compound in a small class. There’s no meaningful RIMA competitor in active research use, which would normally be a strength, but here the class itself hasn’t grown. Toloxatone exists but never achieved the same uptake. So moclobemide defines its category by default. Honest assessment: if your research program isnt specifically about MAO-A biology or RIMA pharmacology, there are more interesting places to put your attention. For investigators who do need that probe, its actually quite useful. For everyone else, it’s a mature approved drug with a story that largely peaked in the nineties.

Novelty

22

Mechanism promise

25

In-category differentiation

48

Evidence quality

58

Translational signal

55

Research bench value

60

Rationale Moclobemide’s reversibility was genuinely innovative in 1989 but that innovation is now fully absorbed into pharmacology textbooks; efficacy trails TCAs, it never achieved FDA approval, and its primary value in 2026 is as the reference compound for MAO-A selectivity experiments. Bench value keeps the score from bottoming out, but near-zero novelty and a saturated mechanism ceiling keep it well below 50.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Reversible MAO-A inhibitor (RIMA)

A morpholine benzamide reversible inhibitor of MAO-A (RIMA); the first MAOI that does not require dietary tyramine restriction.

Abstract

Moclobemide (4-chloro-N-(2-morpholin-4-ylethyl)benzamide; CAS 71320-77-9; molecular formula C13H17ClN2O2; molecular weight 268.74) is a morpholine benzamide reversible inhibitor of MAO-A (RIMA) developed at Roche and approved in Europe (1989) and Canada (1992) under the trade name Aurorix; never FDA approved for the US market. Distinct from earlier MAOIs by reversible binding: tyramine and other dietary substrates can displace moclobemide from MAO-A, eliminating the requirement for tyramine restriction at typical clinical doses. MAO-A selectivity ratio is approximately 100:1 over MAO-B at low doses. Plasma half-life is 1 to 4 hours; the short half-life dictates twice-daily dosing. Hepatic metabolism via CYP2C19 is the primary clearance pathway. Approved for major depressive disorder and social anxiety disorder. The eliminated tyramine restriction has not produced the expected clinical takeoff: efficacy is modestly inferior to TCAs in head-to-head trials, and the drug remains a niche option. Used as the canonical RIMA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-228Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tranylcypromine

Plain-language summaryIntrigue 65 / 100

Tranylcypromine (Parnate) is a first-generation MAOI from 1961 with a chemical backbone closely related to amphetamine. That structural quirk gives it a small but real direct stimulant component on top of the MAO inhibition, producing faster onset (1 to 2 weeks rather than the 4 to 6 weeks typical of MAOIs) and a more activating subjective profile than phenelzine. It carries the same dietary tyramine restrictions and drug interaction risks as the rest of its class. Like phenelzine it earns its place in the modern psychiatric armamentarium specifically for treatment-resistant depression cases where everything else has failed. The recent Tranylcypromine in Treatment-Resistant Depression literature has revived interest in disciplined modern use of these older drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Decades-old irreversible MAOI with real clinical history but negligible frontier research appeal

Look, tranylcypromine is a compound researchers already know. FDA-approved in 1961 under Parnate, it was the first non-hydrazine MAOI and carries a structurally unusual cyclopropylamine scaffold that bears a family resemblance to amphetamine. That amphetamine relationship is actually what makes it marginally more interesting than phenelzine on paper: in addition to irreversible MAO-A and MAO-B inhibition, it produces weak monoamine release, which probably explains the faster clinical onset (1 to 2 weeks versus 3 to 6 for phenelzine) and the mildly activating subjective profile investigators and clinicians have described for decades.

The mechanism, though, isnt novel. Irreversible non-selective MAO inhibition is 60-year-old pharmacology. The tyramine cheese effect is a textbook drug interaction. Plasma half-life is short (1.5 to 3.2 hours) but enzyme recovery is slow (5 to 10 days), which creates the dietary and drug-interaction burden that has made this class clinically awkward and commercially marginal since SSRIs came along. For a bench scientist, that interaction profile isnt interesting, its inconvenient background noise.

Where it retains real, if modest, value is as a reference compound. If your program is probing MAO biology, monoamine release, or you need a positive control in a dopaminergic assay, tranylcypromine is a well-characterized tool with known selectivity and a deep pharmacokinetic record. The (-)-trans isomer is the pharmacologically dominant form; the clinical preparation is racemic, which opens a stereochemistry question that’s occasionally been worth pursuing. And the cyclopropylamine scaffold itself has inspired structural analogs in newer programs, so investigators doing scaffold-level work sometimes keep it on the bench as a structural reference.

We dont think it belongs at the center of a serious research program right now. Treatment-resistant depression is genuinely interesting territory, and MAOIs are experiencing mild clinical rehabilitation in TRD discussions, but that reappraisal largely benefits phenelzine data and the class generally rather than generating new mechanistic questions specific to tranylcypromine. The frontier in TRD has moved toward ketamine, psychoplastogens, and the early GLP-1/neuroinflammation angle. If youre studying MAO biology specifically, selegiline gives you selective MAO-B inhibition for a cleaner dissection. If youre studying irreversible MAO-A, phenelzine has deeper clinical literature.

Tranylcypromine is a mature, approved drug with decades of human data. That means the evidence quality is better than most compounds in this library, and the translational signal is real. But research-merit scoring isnt about knowing a compound works. It’s about whether theres something left to discover. Here, the well is mostly dry.

Novelty

18

Mechanism promise

32

In-category differentiation

38

Evidence quality

60

Translational signal

58

Research bench value

55

Rationale Tranylcypromine scores low on novelty and mechanism because non-selective irreversible MAO inhibition is thoroughly mapped 1960s pharmacology, and the amphetamine-like dual mechanism is a curiosity rather than a research catalyst. Its bench value as a non-hydrazine MAOI reference compound and positive control in monoamine release assays keeps the overall from falling below the low forties, but theres no active frontier here.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Irreversible non-selective MAO inhibitor (amphetamine-related)

A non-hydrazine cyclopropylamine MAOI structurally related to amphetamine; rapid-onset compared to phenelzine.

Abstract

Tranylcypromine ((1S,2R)-2-phenylcyclopropan-1-amine; CAS 155-09-9; molecular formula C9H11N; molecular weight 133.19) is a non-hydrazine cyclopropylamine MAOI approved by the FDA in 1961 under the trade name Parnate. The cyclopropylamine scaffold is structurally related to amphetamine, producing weak monoamine release in addition to MAO inhibition; the result is faster antidepressant onset (1 to 2 weeks) than phenelzine (3 to 6 weeks) and a mildly activating subjective profile. Inhibition of both MAO-A and MAO-B is irreversible, with similar tyramine cheese-effect risk. Plasma half-life is 1.5 to 3.2 hours, but enzyme inhibition persists for 5 to 10 days. The (-)-trans isomer is the predominant active form; clinical preparations are racemic. Hepatic metabolism is minor; the compound is largely excreted unchanged. Approved for major depressive disorder; used in atypical and treatment-resistant depression. Used as a non-hydrazine MAOI reference compound and as a positive control in dopaminergic and norepinephrine release studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-227Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Phenelzine

Plain-language summaryIntrigue 64 / 100

Phenelzine (Nardil) is a first-generation, non-selective MAOI from 1961 that irreversibly destroys both forms of monoamine oxidase, the enzymes that break down serotonin, norepinephrine, and dopamine. The result is a powerful boost in all three neurotransmitters but with the famous catch: any food containing tyramine (aged cheese, cured meats, fermented soy, certain wines) can trigger a hypertensive crisis severe enough to cause stroke, because the gut enzymes that normally clear dietary tyramine are gone. Many drug interactions are similarly dangerous. Despite all this, phenelzine remains genuinely useful for atypical depression and treatment-resistant depression where SSRIs and SNRIs have failed, because the broad monoamine boost can succeed where narrower drugs have not. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

A first-generation MAOI whose research moment passed decades ago; niche clinical value, minimal frontier interest

Look, phenelzine is sixty-plus years old. FDA cleared in 1961, it’s one of the original hydrazine MAOIs, and the research community has had decades to pick it apart. The mechanism is well understood, the liabilities are well documented, and the clinical niche it occupies, atypical and treatment-resistant depression, has been carved out since the 1970s. That doesnt make it useless, but it does make it exactly the kind of compound that scores low on a research-merit rubric built to surface things worth investigating right now.

The mechanism is genuinely interesting pharmacologically, just not novel. Phenelzine covalently inactivates both MAO-A and MAO-B by forming a hydrazine adduct at the FAD prosthetic group. Because the inhibition is irreversible, the effective duration of enzyme suppression is 14 to 21 days, fully decoupled from the plasma half-life of 11.6 hours. This produces sustained, non-selective monoamine elevation across serotonin, norepinephrine, and dopamine pathways simultaneously. There’s also a secondary angle that doesn’t get nearly enough attention: phenelzine’s hydrazine metabolites inhibit GABA transaminase, raising GABAergic tone and likely contributing to its efficacy in PTSD and anxious depression. We think that angle is legitimately underexplored. But calling it a novel mechanism in 2025 would be a stretch.

The tyramine problem is the defining liability. Dietary tyramine, normally cleared by intestinal MAO-A, accumulates under full MAO blockade and triggers norepinephrine release from sympathetic terminals, producing hypertensive crisis. The dietary restrictions are real and onerous. Modern selective reversible inhibitors like moclobemide avoid most of this, and that makes phenelzine a harder sell as a primary research focus. For basic MAO biology, cleaner tools exist: clorgyline (selective MAO-A) and low-dose selegiline (selective MAO-B) give mechanistically tighter answers without the tyramine confound.

The evidence base is real, if dated. Multiple controlled trials from the 1960s through the 1980s established efficacy in atypical depression, and the Quitkin group’s classification of atypical features, mood reactivity, hypersomnia, leaden paralysis, rejection sensitivity, was built partly around phenelzine response profiles. VA collaborative work extended phenelzine’s profile into PTSD. The clinical signal is not in doubt. The methodology is just pre-modern by current RCT standards.

We don’t see phenelzine as a compelling research target for most programs right now. It retains a specific clinical role for patients who’ve failed SSRIs, SNRIs, and TCAs, and it’s a genuine landmark in the history of biological psychiatry. But as a probe, cleaner selective tools exist. As a novel indication target, the low-hanging fruit has been picked. Honest score: this is a 1960s compound with a narrow remaining niche, not something sitting at the frontier of anything active.

Novelty

12

Mechanism promise

22

In-category differentiation

28

Evidence quality

58

Translational signal

68

Research bench value

35

Rationale Phenelzine is a 1961-approved hydrazine MAOI with fully characterized mechanism and mature evidence base; novelty and differentiation are both very low, held up only by evidence and translational scores reflecting genuine historical clinical work. No structural cap binds, but the raw calculation lands near 35 regardless.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Irreversible non-selective MAO inhibitor (hydrazine)

A first-generation hydrazine MAOI; a non-selective irreversible inhibitor still used for atypical and treatment-resistant depression.

Abstract

Phenelzine (2-phenylethylhydrazine; CAS 51-71-8; molecular formula C8H12N2; molecular weight 136.19) is a hydrazine class non-selective irreversible monoamine oxidase inhibitor approved by the FDA in 1961 under the trade name Nardil. The compound covalently inactivates both MAO-A and MAO-B by hydrazine-mediated cofactor adduction at the FAD prosthetic group; recovery requires de novo enzyme synthesis (approximately 14 to 21 days). The non-selective inhibition increases brain serotonin, norepinephrine, and dopamine concurrently, producing classical MAOI antidepressant pharmacology along with the well-known tyramine cheese-effect risk: dietary tyramine, normally degraded by intestinal MAO-A, accumulates and triggers hypertensive crisis through indirect sympathomimetic action. Plasma half-life is 11.6 hours, but the irreversible binding produces effective enzyme inhibition for 2 to 3 weeks. Hydrazine metabolism may produce hepatotoxic byproducts; chronic dosing requires hepatic monitoring. Approved for major depressive disorder; remains a benchmark for atypical depression with reverse vegetative features and for treatment-resistant cases where SSRIs and TCAs have failed.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-226Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Rasagiline

Plain-language summaryIntrigue 66 / 100

Rasagiline (Azilect) is a second-generation MAO-B inhibitor from Teva, approved by the FDA in 2006 for Parkinson disease. It is structurally distinct from selegiline (built around an indane scaffold rather than a phenethylamine) and the key practical advantage is that the body does not break it down into amphetamine derivatives. That eliminates one of the more annoying features of selegiline and makes drug screening cleaner. Like selegiline it binds MAO-B irreversibly, so a single daily dose keeps the enzyme suppressed for weeks. The ADAGIO trial controversially suggested it might also slow disease progression rather than just treat symptoms, although that finding has not been universally accepted. Used as monotherapy in early Parkinson and as an add-on in advanced disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature MAO-B reference standard with solid clinical evidence but limited frontier research appeal

Rasagiline is the second-generation irreversible MAO-B inhibitor that largely displaced selegiline’s role in Parkinson pharmacology by doing one thing better: it doesn’t metabolize to amphetamines. That’s a meaningful difference in practice. No methamphetamine or l-amphetamine metabolites means cleaner drug-screen profiles, no cardiovascular overstimulation at clinical doses, and no tyramine restriction at the approved 1 mg daily dose. Teva’s development team got this right, and the FDA agreed in 2006. The PRESTO, TEMPO, and LARGO trials gave it solid regulatory legs across both monotherapy and levodopa-adjunct settings.

The more interesting research angle isnt the MAO-B inhibition itself, which is textbook at this point, but the propargylamine-mediated neuroprotection signal that sits underneath it. The propargyl group appears to influence Bcl-2 family expression, APP processing, and mitochondrial membrane stability through mechanisms that are partly independent of MAO-B. The ADAGIO delayed-start trial tried to pin this down. At 1 mg, it showed a weak disease-modification signal; at 2 mg, it didn’t, which muddied the interpretation. The FDA reviewed this carefully and declined a neuroprotection label claim, but the biological question isnt fully closed, and several groups have continued probing propargylamine biology in cell and rodent models. Thats where the remaining bench interest lives.

Here’s the thing though: rasagiline isnt on the frontier anymore. Safinamide arrived as a reversible, selective MAO-B inhibitor with an additional sodium-channel and glutamate-release angle that gives it a more interesting pharmacological story for combination PD research. The longevity-oriented MAO-B work has largely migrated toward broader monoamine biology in the context of aging rather than Parkinson’s specifically, and rasagiline doesn’t have the novel positioning to anchor that conversation the way a mitochondrial-targeted peptide or an mTOR-adjacent compound might. Its 14:1 MAO-B selectivity is good; it’s just not surprising anymore.

We think rasagiline earns its place in a research library as a reference standard rather than a frontier target. If your program involves dopamine metabolism, MAO-B selectivity profiling, or the propargylamine neuroprotection hypothesis, it’s a clean, well-sourced, thoroughly characterized tool. The irreversible kinetics are well-documented; the approximately 14-day recovery period is practically useful for experimental design. It’s just not a compound where bench work is likely to surface surprising findings in 2026. The primary questions have been asked, the big trials are done, and the remaining uncertainty around neuroprotection is real but not easily resolved at bench scale. Solid compound. Not an exciting one.

Novelty

22

Mechanism promise

38

In-category differentiation

42

Evidence quality

72

Translational signal

68

Research bench value

52

Rationale Rasagiline scores well on evidence and translational signal as an FDA-approved Phase 3-validated drug, but nearly 20 years of market presence and a fully characterized mechanism drag novelty and differentiation down sharply; safinamide’s reversible inhibition plus glutamate-modulation angle has moved the field forward, leaving rasagiline as a clean reference compound rather than a compelling new research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective irreversible MAO-B inhibitor (second-generation)

A second-generation propargyl MAO-B inhibitor lacking the amphetamine metabolites of selegiline.

Abstract

Rasagiline ((R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; CAS 136236-51-6; molecular formula C12H13N; molecular weight 171.24) is a second-generation irreversible MAO-B inhibitor developed at Teva and approved by the FDA in 2006 under the trade name Azilect. Structurally distinct from selegiline by the indane scaffold replacing the phenethylamine, rasagiline does not yield amphetamine-class metabolites, simplifying its drug screening profile and avoiding the subjective stimulation associated with selegiline. MAO-B selectivity is approximately 14:1 over MAO-A at clinical dose (1 mg daily); the inhibition is irreversible and recovery requires de novo enzyme synthesis (approximately 14-day washout). Approved as monotherapy in early Parkinson disease and as adjunct to levodopa in advanced disease. The ADAGIO trial suggested possible disease-modifying effect for the 1 mg dose, though this remains debated. Tyramine restriction is not required at 1 mg daily; at higher experimental doses (2 mg) the cheese-effect risk emerges. Plasma half-life is approximately 3 hours, but the irreversible binding produces effective enzyme inhibition for weeks. Used as a reference second-generation MAO-B inhibitor in Parkinson research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-225Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Selegiline

Plain-language summaryIntrigue 70 / 100

Selegiline is a Hungarian discovery by Joseph Knoll from the 1960s that selectively and irreversibly knocks out MAO-B, an enzyme that breaks down dopamine in the brain. At low oral doses (5 to 10 mg) it is used to slow Parkinson disease progression; at higher doses it loses its selectivity and starts inhibiting MAO-A as well, which produces antidepressant effects but reintroduces the dietary tyramine restrictions that make MAOIs cumbersome. A skin patch formulation (Emsam) bypasses the gut MAO-A, allowing depression-strength dosing without the cheese-effect risk. The body breaks selegiline down into amphetamine and methamphetamine as metabolites, which contribute to its stimulant feel and complicate its use in patients screened for substance use. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

43/100

Mature MAO-B reference tool largely superseded by rasagiline for new bench programs

Look, selegiline has been around since Joseph Knoll’s group in Hungary in the 1960s, and the literature around it is enormous. DATATOP enrolled over 800 patients and remains one of the cleaner neuroprotection trials in movement disorders, even if the disease-modification question never fully resolved. The FDA approval for Parkinson disease (oral) and for depression via the Emsam transdermal patch is genuine clinical validation. We dont dismiss that.

But when you’re evaluating selegiline as a research target today, you’re working with a compound that has almost no uncharted surface area in its primary mechanism. Irreversible MAO-B inhibition via the propargyl moiety is understood at the crystallographic level. The selectivity window (approximately 100:1 MAO-B over MAO-A at low oral doses, collapsing above 20 mg daily) has been characterized exhaustively. The tyramine interaction is fully mapped. The amphetamine and methamphetamine metabolites are the well-known complication. Thats the whole compound, mechanistically speaking.

The more interesting angle is the neuroprotection hypothesis that runs independent of MAO inhibition. The propargylamine pharmacophore activates anti-apoptotic pathways (Bcl-2 upregulation, GAPDH nuclear translocation blockade) in a way that appears enzyme-independent. Selegiline and rasagiline both show this in vitro. Here’s the problem: rasagiline is now the preferred probe for that biology. Cleaner metabolite profile, no amphetamine byproducts, more potent MAO-B IC50. If youre investigating propargylamine neuroprotection, youre probably reaching for rasagiline, not selegiline.

The Emsam story does deserve credit. Bypassing first-pass GI MAO-A inhibition to achieve antidepressant plasma levels without tyramine restriction at the low-dose patch is genuinely clever delivery pharmacology. The FDA approved it in 2006 and theres real efficacy data behind it. But the depression mechanism itself isnt a frontier question; MAOI pharmacology is mature, and the clinical outcomes from Emsam are established. There isnt much new to discover there.

We think selegiline belongs in a well-stocked reference library as exactly what it is: the original selective MAO-B inhibitor, a critical historical reference compound, and occasionally the right tool when matched comparators to early Parkinson trial design matter. For new research programs asking novel questions in dopaminergic biology, MAO-B selectivity, or propargylamine neuroprotection, rasagiline now sets the standard. Selegiline earns its place, but it’s not where the interesting questions are being answered right now.

Novelty

18

Mechanism promise

38

In-category differentiation

28

Evidence quality

72

Translational signal

68

Research bench value

52

Rationale Selegiline is a 1960s compound with FDA approval in two indications and an enormous clinical literature; its mechanism is resolved at the crystallographic level, its metabolite liabilities are fully characterized, and rasagiline now dominates the propargylamine MAO-B niche with cleaner pharmacology. Evidence quality and translational signal are high because it’s an approved drug, but novelty and differentiation pull the overall score firmly into established-mature territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective irreversible MAO-B inhibitor

A propargyl phenethylamine MAO-B inhibitor used in Parkinson disease and at higher doses in depression via MAO-A engagement.

Abstract

Selegiline ((R)-N-methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine; CAS 14611-51-9; molecular formula C13H17N; molecular weight 187.28) is an irreversible propargyl-substituted MAO-B inhibitor developed by Joseph Knoll in Hungary in the 1960s. At low oral doses (5 to 10 mg daily) the compound is selective for MAO-B (selectivity ratio approximately 100:1 over MAO-A), preventing dopamine catabolism in the basal ganglia and providing modest symptomatic benefit and possibly disease-modifying effect in Parkinson disease (DATATOP trial). At higher doses (above 20 mg daily) selectivity is lost and MAO-A inhibition contributes, producing classical MAOI antidepressant pharmacology with the corresponding tyramine cheese-effect risk. The transdermal patch (6 to 12 mg/24 h, Emsam) achieves antidepressant plasma levels while bypassing first-pass GI MAO-A inhibition, mitigating the tyramine restriction at the low-dose patch (6 mg). Metabolites include amphetamine and methamphetamine, contributing to subjective alertness and complicating drug screening. Used as a reference MAO-B selective inhibitor in Parkinson research and as a transdermal MAOI in depression studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-224Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 47 48 49 50 51 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.